These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Post-transplantation Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography in Patients with Lymphoblastic Lymphoma is an Independent Prognostic Factor with an Impact on Progression-Free Survival but not Overall Survival. Dai N; Liu H; Deng S; Sang S; Wu Y Technol Cancer Res Treat; 2021; 20():15330338211056478. PubMed ID: 34806464 [No Abstract] [Full Text] [Related]
3. Deauville Scores 4 or 5 Assessed by Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Early Post-Allotransplant Is Highly Predictive of Relapse in Lymphoma Patients. Bouard L; Bodet-Milin C; Bailly C; Guillaume T; Peterlin P; Garnier A; Bourgeois AL; Mahé B; Dubruille V; Blin N; Touzeau C; Gastinne T; Lok A; Bonnet A; Béné MC; Gouill SL; Moreau P; Kraeber-Bodéré F; Chevallier P Biol Blood Marrow Transplant; 2019 May; 25(5):906-911. PubMed ID: 30481598 [TBL] [Abstract][Full Text] [Related]
4. Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation. Spaepen K; Stroobants S; Dupont P; Vandenberghe P; Maertens J; Bormans G; Thomas J; Balzarini J; De Wolf-Peeters C; Mortelmans L; Verhoef G Blood; 2003 Jul; 102(1):53-9. PubMed ID: 12609836 [TBL] [Abstract][Full Text] [Related]
5. The role of positron emission tomography with 18F-fluorodeoxyglucose integrated with computed tomography in the evaluation of patients with multiple myeloma undergoing allogeneic stem cell transplantation. Patriarca F; Carobolante F; Zamagni E; Montefusco V; Bruno B; Englaro E; Nanni C; Geatti O; Isola M; Sperotto A; Buttignol S; Stocchi R; Corradini P; Cavo M; Fanin R Biol Blood Marrow Transplant; 2015 Jun; 21(6):1068-73. PubMed ID: 25754658 [TBL] [Abstract][Full Text] [Related]
6. Conventional allogeneic hematopoietic stem cell transplantation for lymphoma may overcome the poor prognosis associated with a positive FDG-PET scan before transplantation. Yoshimi A; Izutsu K; Takahashi M; Kako S; Oshima K; Kanda Y; Motokura T; Chiba S; Momose T; Ohtomo K; Kurokawa M Am J Hematol; 2008 Jun; 83(6):477-81. PubMed ID: 18266206 [TBL] [Abstract][Full Text] [Related]
7. Impact of Pretransplantation (18)F-Fluorodeoxyglucose-Positron Emission Tomography on Survival Outcomes after T Cell-Depleted Allogeneic Transplantation for Hodgkin Lymphoma. Reyal Y; Kayani I; Bloor AJC; Fox CP; Chakraverty R; Sjursen AM; Fielding AK; Ben Taylor M; Bishton MJ; Morris EC; Thomson KJ; Russell N; Mackinnon S; Peggs KS Biol Blood Marrow Transplant; 2016 Jul; 22(7):1234-1241. PubMed ID: 27095691 [TBL] [Abstract][Full Text] [Related]
8. Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation. Becherer A; Mitterbauer M; Jaeger U; Kalhs P; Greinix HT; Karanikas G; Pötzi C; Raderer M; Dudczak R; Kletter K Leukemia; 2002 Feb; 16(2):260-7. PubMed ID: 11840293 [TBL] [Abstract][Full Text] [Related]
9. Prognostic Value of FDG PET/CT before Allogeneic and Autologous Stem Cell Transplantation for Aggressive Lymphoma. Ulaner GA; Goldman DA; Sauter CS; Migliacci J; Lilienstein J; Gönen M; Schöder H; Moskowitz CH; Zelenetz AD Radiology; 2015 Nov; 277(2):518-26. PubMed ID: 26035588 [TBL] [Abstract][Full Text] [Related]
10. Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma. Derenzini E; Musuraca G; Fanti S; Stefoni V; Tani M; Alinari L; Venturini F; Gandolfi L; Baccarani M; Zinzani PL Cancer; 2008 Nov; 113(9):2496-503. PubMed ID: 18833583 [TBL] [Abstract][Full Text] [Related]
11. Favorable outcomes from allogeneic and autologous stem cell transplantation for patients with transformed nonfollicular indolent lymphoma. Villa D; George A; Seymour JF; Toze CL; Crump M; Lee C; Buckstein R; Stewart DA; MacDonald D; Foley R; Xenocostas A; Sabloff M; Chua N; Couture F; Larouche JF; Cohen S; Savage KJ; Connors JM; Panzarella T; Carney DA; Dickinson M; Kuruvilla J Biol Blood Marrow Transplant; 2014 Nov; 20(11):1813-8. PubMed ID: 25042735 [TBL] [Abstract][Full Text] [Related]
12. A phase II study of a nonmyeloablative allogeneic stem cell transplant with peritransplant rituximab in patients with B cell lymphoid malignancies: favorably durable event-free survival in chemosensitive patients. Sauter CS; Barker JN; Lechner L; Zheng J; Devlin SM; Papadopoulos EB; Perales MA; Jakubowski AA; Goldberg JD; Koehne G; Ceberio I; Giralt S; Zelenetz AD; Moskowitz CH; Castro-Malaspina H Biol Blood Marrow Transplant; 2014 Mar; 20(3):354-60. PubMed ID: 24315843 [TBL] [Abstract][Full Text] [Related]
14. The value of complete remission according to positron emission tomography prior to autologous stem cell transplantation in lymphoma: a population-based study showing improved outcome. Noring K; Carlsten M; Sonnevi K; Wahlin BE BMC Cancer; 2021 May; 21(1):500. PubMed ID: 33947353 [TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of FDG-PET in relapsed or refractory classical Hodgkin lymphoma treated with standard salvage chemotherapy and autologous stem cell transplantation. Smeltzer JP; Cashen AF; Zhang Q; Homb A; Dehdashti F; Abboud CN; Dipersio JF; Stockerl-Goldstein KE; Uy GL; Vij R; Westervelt P; Bartlett NL; Fehniger TA Biol Blood Marrow Transplant; 2011 Nov; 17(11):1646-52. PubMed ID: 21601641 [TBL] [Abstract][Full Text] [Related]